Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
What Regeneron Pharmaceuticals (REGN)'s Expanded EU Pediatric Approval for Dupixent Means For Shareholders
Regeneron Pharmaceuticals and Sanofi received EU approval for Dupixent to treat moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11. This expands Dupixent’s market, reinforcing its immunology role and diversifying Regeneron’s revenue beyond Eylea amid increasing competition. The approval supports Regeneron’s broader strategy to enhance its pipeline and maintain margins despite market pressures.